Sunpointe’s Gilead Sciences GILD Stock Holding History

Sunpointe’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$351K	Sell	2,521 -861	-25%	-$121K	0.12%	172
2025 Q4	$415K	Sell	3,382 -23	-0.7%	-$2.79K	0.14%	153
2025 Q3	$378K	Sell	3,405 -342	-9%	-$38.9K	0.14%	158
2025 Q2	$415K	Buy	3,747 +55	+1%	+$5.85K	0.16%	126
2025 Q1	$414K	Sell	3,692 -962	-21%	-$99.3K	0.22%	88
2024 Q4	$430K	Buy	4,654 +500	+12%	+$45K	0.22%	90
2024 Q3	$348K	Buy	4,154 +155	+4%	+$11.8K	0.29%	91
2024 Q2	$274K	Sell	3,999 -1,001	-20%	-$66.8K	0.18%	114
2024 Q1	$366K	Buy	5,000 +1,509	+43%	+$116K	0.41%	78
2023 Q4	$283K	Buy	+3,491	New	+$272K	0.36%	92

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sunpointe's GILD Position: Q1 2026 in Review

Sunpointe reduced its Gilead Sciences (GILD) stake by 25% in Q1 2026, selling an estimated $121K and leaving 2,521 shares worth $351K. The position accounts for 0.12% of the portfolio, ranked #172.

Sunpointe first reported a position in GILD in Q4 2023 and has held it in 10 quarters since. The position peaked at $430K in Q4 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Sunpointe held 2,521 shares of Gilead Sciences worth $351K as of Q1 2026.
Sunpointe sold 861 Gilead Sciences shares in Q1 2026, an estimated $121K.
Gilead Sciences made up 0.12% of Sunpointe's portfolio in Q1 2026, its #172 holding.
Sunpointe first reported a position in Gilead Sciences in Q4 2023 and has held it in 10 quarters since.
Sunpointe's Gilead Sciences position peaked at $430K in Q4 2024.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Sunpointe's 13F filing for Q1 2026, filed 21 Apr 2026.